U.S. Continuous Glucose Monitoring Devices Market Revenue & Forecast Analysis, 2026-2035

The U.S. continuous glucose monitoring devices market size was evaluated at USD 5.0 billion in 2025. The market is expected to grow at a CAGR of 12.9% from USD 5.6 billion in 2026 to USD 16.7 billion in 2035. The market is propelled by the growing incidence of diabetes, heightened need for real-time glucose monitoring, broader insurance coverage, and innovations in wearable sensor technology. Additionally, increased use of connected diabetes-care solutions and OTC CGM devices is expanding access to glucose monitoring.

Published: October 14, 2026
100 Pages

Market Overview

According to the U.S. Centres for Disease Control and Prevention (CDC), approximately 40.1 million Americans had diagnosed or undiagnosed diabetes in 2023, representing 12% of the U.S. population.

The U.S. continuous glucose monitoring (CGM) devices market has experienced steady growth, driven by rising diabetes prevalence, increasing adoption of real-time glucose tracking, and advances in wearable sensor technology. Growing awareness of the benefits of continuous monitoring and the need to reduce reliance on frequent finger-stick testing have further supported market adoption. For instance, in 2024, Abbott expanded U.S. access to its over-the-counter Lingo glucose biosensor, reflecting growing demand for convenient, wearable glucose-monitoring solutions.

The U.S. CGM devices market is expected to maintain steady growth as diabetes management increasingly shifts toward connected monitoring, personalised treatment, and convenient wearable technologies. Further integration with smartphone applications, digital health platforms, and automated insulin-delivery systems is expected to strengthen demand. For instance, in July 2026, Dexcom raised its full-year revenue forecast following stronger-than-expected demand for its continuous glucose monitoring devices, highlighting continued commercial momentum in the sector.

U.S. Continuous Glucose Monitoring Devices Market Overview

Base Year Market Size (2025): USD 5.0 Billion

CAGR: 12.9%

Forecast Year Market Size (2035): USD 16.7 Billion

Major Players:

  • Abbott Laboratories

  • Dexcom, Inc.

  • F. Hoffmann-La Roche Ltd.

  • Medtronic plc

  • Senseonics Holdings, Inc.

U.S. Continuous Glucose Monitoring Devices Market Trends

The U.S. CGM market is shifting toward more reachable, interconnected, and tailored glucose tracking. Major trends encompass the growth of over-the-counter devices, AI-driven glucose analysis, extended-wear sensors, and connectivity with digital diabetes management systems.

· Non-prescription CGMs are becoming available to more eligible individuals, including adults not on insulin and those focused on metabolic health.

· AI-driven functionalities assist users in analysing glucose trends, recognising meal-associated variations, and obtaining tailored insights.

· Producers are developing sensors intended to function for extended durations, decreasing the need for replacements and enhancing convenience.

· Furthermore, companies are promoting specific CGM products for qualified individuals who want to learn how nutrition, physical activity, and everyday practices impact glucose levels.

Collectively, the market is moving toward longer-wear sensors, smarter data interpretation, and wider access to connected glucose-monitoring solutions.

U.S. Continuous Glucose Monitoring Devices Market Analysis

By Product Type

Sensors enable continuous measurement of glucose levels in interstitial fluid, providing frequent readings and glucose-trend data that support diabetes management and timely treatment decisions.

Based on product type, the U.S. continuous glucose monitoring devices market is categorized into sensors, devices/readers, applicators, and transmitters. Sensors hold the largest share at 61.31% in 2025.

By Connectivity Outlook

Bluetooth enables wireless transmission of real-time glucose readings from CGM sensors to compatible smartphones, readers, and insulin-delivery systems, supporting convenient monitoring and timely glucose alerts.

Based on connectivity, the U.S. continuous glucose monitoring devices market is categorized into Bluetooth, 4G/cellular, and near field communication (NFC). Bluetooth holds the largest share in 2025.

By End-use

Home Care Settings enable patients to monitor glucose levels continuously during daily activities, supporting self-management, timely treatment adjustments, and convenient diabetes care outside clinical facilities.

Based on end-use, the U.S. continuous glucose monitoring devices market is categorised into home care settings, hospitals & clinics, and ambulatory care centres. Home Care Settings hold the largest share in 2025.

Key Companies Profiled

The U.S. continuous glucose monitoring (CGM) devices market is highly concentrated, with Dexcom and Abbott Laboratories serving as leading competitors. Other established players include Medtronic, F. Hoffmann-La Roche, and Senseonics. These companies compete through sensor accuracy, wear duration, product usability, clinical integration, and distribution networks, while expanding their portfolios to address diverse diabetes-management needs.

Competition is increasingly driven by longer-wear sensors, smartphone connectivity, automated insulin delivery integration, and expanded access through over-the-counter products. Companies are also strengthening digital health capabilities and collaborating with healthcare providers to improve access and patient engagement. These developments are broadening CGM adoption among people with type 1 and type 2 diabetes and selected consumers interested in metabolic health monitoring.

U.S. Continuous Glucose Monitoring Devices Market Companies:

  • A. Menarini Diagnostics S.r.l.

  • Abbott Laboratories

  • Ascensia Diabetes Care

  • Dexcom, Inc.

  • F. Hoffmann-La Roche Ltd.

  • i-SENS, Inc.

  • Insulet Corporation

  • Medtronic plc

  • Medtrum Technologies Inc.

  • Nemaura Medical, Inc.

  • Senseonics Holdings, Inc.

  • Tandem Diabetes Care, Inc.

  • Ypsomed AG

Market Segmentation

This study provides revenue growth and emerging trends across global, regional, and country levels from 2021 to 2035, segmenting the U.S. continuous glucose monitoring devices market by-

Product Type (Revenue in USD Billion, 2021 - 2035)

  • Sensors

  • Device/Readers

  • Applicators

  • Transmitters

Connectivity Outlook (Revenue in USD Billion, 2021 - 2035)

  • Bluetooth

  • 4G/Cellular

  • Near Field Communication (NFC)

Indication (Revenue in USD Billion, 2021 – 2035)

  • Type 1 Diabetes

  • Type 2 Diabetes

  • Gestational Diabetes

  • Others

End-use (Revenue in USD Billion, 2021 – 2035)

  • Home Care Settings

  • Hospitals & Clinics

  • Ambulatory Care Centers

Table of Content

1. Methodology and Scope

1.1. Scope of the Study

1.1.1. Market Segmentation

1.1.2. Market Definition

1.1.3. Inclusions and Exclusions of the Study

1.2. Research Design

1.2.1. Base Year, Historical Data, and Forecast Period

1.2.2. Data Collection Methods

1.2.2.1. Secondary Sources

1.2.2.2. Primary Sources

1.2.3. Research Methodology

1.2.3.1. Base Year Calculation/ Parent Market Analysis, Company/ Brand Share Analysis, 2025 (Top-down Approach)

1.2.3.2. Volume-Price Approach (Bottom-up Approach)

1.2.3.3. Data Triangulation

1.2.4. Forecasting Model

1.3. Research Assumptions

1.4. Validation and Data Quality Control

1.5. List of Primary Sources

1.6. List of Secondary Sources

2. Executive Summary

2.1. Market Overview

2.2. Segment Snapshot

2.3. Competitive Landscape Snapshot

3. Industry Outlook

3.1. Industry Ecosystem Analysis

3.2. Parent/ Ancillary Market Analysis

3.3. Market Dynamics

3.3.1. Drivers

3.3.2. Restraints/ Challenges

3.3.3. Opportunities

3.4. Value Chain Analysis

3.5. Technology Roadmap

3.6. Porters Analysis

3.7. PESTLE Analysis

4. Market Estimates and Forecasts, By Product Type, 2021 - 2035 (Market Size in USD Bn)

4.1. Sensors

4.2. Device/Readers

4.3. Applicators

4.4. Transmitters

5. Market Estimates and Forecasts, By Connectivity Outlook, 2021 – 2035 (USD Bn)

5.1. Bluetooth

5.2. 4G/Cellular

5.3. Near Field Communication (NFC)

6. Market Estimates and Forecasts, By Indication, 2021 – 2035 (USD Bn)

6.1. Type 1 Diabetes

6.2. Type 2 Diabetes

6.3. Gestational Diabetes

6.4. Others

7. Market Estimates and Forecasts, By End-use, 2021 – 2035 (USD Bn)

7.1. Home Care Settings

7.2. Hospitals & Clinics

7.3. Ambulatory Care Centers

8. Market Estimates and Forecasts, By U.S., 2021 - 2035 (USD Bn)

8.1.1. U.S.

8.1.1.1. U.S. Continuous Glucose Monitoring Devices Market Estimates and Forecasts to 2035 (USD Bn)

8.1.1.2. Market Dynamics

8.1.1.3. Competitive Landscape

8.1.1.4. Regulatory Framework

8.1.1.5. Reimbursement Scenario

9. Competitive Landscape

9.1. Company Market Share Analysis, 2025

9.2. Company Tier Structure

9.3. List of Major Suppliers, By Key Countries

9.4. Key Company Positioning Analysis

9.5. Company Profile

9.5.1. Abbott Laboratories

9.5.2. Ascensia Diabetes Care

9.5.3. Dexcom, Inc.

9.5.4. F. Hoffmann-La Roche Ltd.

9.5.5. i-SENS, Inc.

9.5.6. Insulet Corporation

9.5.7. Medtronic plc

9.5.8. Medtrum Technologies Inc.

9.5.9. Nemaura Medical, Inc.

9.5.10. Senseonics Holdings, Inc.

9.5.11. Tandem Diabetes Care, Inc.

9.5.12. Ypsomed AG

10. Analyst Perspective

11. Related Reports

Revolution Insights Briefs

Stay informed with updates on related market reports and key industry topics.